and 19 cm2 were applied to the shaved chests of Parkinsonian monkeys. Locomotor activity was increased according to the skin surface area available for transdermal absorption, and was restored to the range observed in normal, untreated monkeys throughout a 24 h period using a surface area of 4-9-19 cm2. Comparing the minimum dose of (+ ) -PHNO required for restoration of locomotor activity to normal levels by the subcutaneous and transdermal routes (2 5 pg/kg/h and 4-78 cm2, respectively), we would estimate the systemic availability of (+ ) -PHNO using the transdermal patch to be < 20% of the in vitro release rate. Analysis of plasma levels of( + ) -PHNO in a single animal treated with transdermal patches covering an area of either 2-4 or 9-6 cm2 indicated a lag period of approximately 12 h before stable plasma levels were attained; thereafter plasma concentrations of (+) -PHNO remained stable throughout the following 36 h period until the patches were removed at 48 h. Steady state plasma levels of (+ ) -PHNO were proportional to the surface area of skin exposed to the transdermal delivery system (approximately 100 pg/ml using a patch size of 2-4 cm2, and 500-600 pg/ml for a total patch size of 9-6 cm2; table).
Our findings indicate that plasma levels of (+)-PHNO within the therapeutic range may be achieved and sustained for at least 24 h using rate-controlled transdermal absorption, and suggest a novel sustained release delivery system for antiparkinsonian therapy. 
